From the AACR abstract associated with todays PR; wow.
In this stringent established-tumor model, NLG919 plus pmel 1/vaccine produced a dramatic collapse of tumor size within 4 days of vaccination (~95% reduction in tumor volume compared to control animals receiving pmel-1/vaccine alone without NLG919).
In cancer, IDO activity helps to promote acquired tolerance to tumor antigens. This is a big problem and is one of the reasons why traditionally chemotherapy ultimately fails.
D-1-methyl-tryptophan (Indoximid) can be used as an adjuvant with standard chemo to block host mediated immunosuppression and enhance antitumor immunity. Because Indoxomid is complimentary to standard chemotherapy, the commercial implications are significant. The end game is Hyperacute therapy plus Indoxomid. Note NLNk appear to be optimiziing the structure/activity to enhance efficacy.